March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
February 2026 in “International Journal of Clinical Pharmacy” Pharmacy care clinics can reduce some emergency visits by managing certain conditions and medication issues.
February 2026 in “Frontiers in Immunology” Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
January 2026 in “Frontiers in Immunology” Icariin can regulate macrophages and may help treat inflammation, cancer, bone disorders, and fibrotic diseases.
January 2026 in “Forum Dermatologicum” JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
January 2026 in “Biomaterials Science” The formulation helps improve wound healing and skin repair.
January 2026 in “Immune Network” Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
January 2026 in “Food and Feed Research” Bananas have many health benefits, including treating diarrhea, diabetes, and colds.
December 2025 in “Al-Iraqia Medical College Journal” Virus infection risk is linked to heat tolerance and size, but decreases with high humidity and mutation rate.
November 2025 in “Frontiers in Medicine” Baseline severity and relapse history affect alopecia areata treatment and recurrence.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
PRP may help reduce brain inflammation and protect brain cells.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tattoos may trigger autoimmune symptoms in some people.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
September 2025 in “Journal of Phytonanotechnology and Pharmaceutical Sciences” Licorice has health benefits but can also cause side effects, so it should be used carefully.
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
Baricitinib is more effective than methotrexate for severe alopecia areata.
February 2025 in “Journal of Nutrients” Bone broth may improve health and prevent diseases.
February 2025 in “Frontiers in Veterinary Science” Prussian Blue successfully treated thallium poisoning in a dog.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
January 2025 in “Open Life Sciences” Overexpression of the HE4 gene in mice causes eye inflammation and cloudiness.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
December 2024 in “Research Journal for Social Affairs” PCOS causes hormonal issues and infertility, with treatment options including medication and lifestyle changes.
December 2024 in “THE SCIENTIFIC TEMPER” Women in Raichur slums need better health awareness and medical help.
November 2024 in “International Journal of Agricultural Invention” Amla is a nutritious fruit with many health benefits, including boosting immunity and fighting diseases.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.
November 2024 in “International Journal of Research and Review” Nanotechnology improves cosmetics by enhancing ingredient delivery and effectiveness.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.